Invicta Diagnostic Reports FY26 Net Profit of ₹4.87 Cr
Invicta Diagnostic Limited reported a total income of ₹33.04 Cr for FY26, up from ₹30.18 Cr in the previous year, with a net profit of ₹4.87 Cr. EBITDA increased to ₹10.45 Cr, achieving a margin of 31.63%. The company expanded its operations through a joint venture in Pune, the commencement of the Dadar Centre, and the acquisition of a stake in Vinchurkar Diagnostics.
*this image is generated using AI for illustrative purposes only.
Invicta Diagnostic Limited has announced its audited financial results for the financial year ended March 31, 2026. The company reported a total income of ₹33.04 Cr for FY26, compared to ₹30.18 Cr in the previous year. Net profit for the period stood at ₹4.87 Cr, while EBITDA increased to ₹10.45 Cr from ₹9.29 Cr annually. The audited standalone and consolidated financial results were considered and adopted in the Board Meeting held on May 18, 2026.
Financial Performance
The company achieved an EBITDA margin of 31.63% for FY26, up from 30.78% in the previous year. For the second half of FY26, total income was recorded at ₹15.96 Cr with a net profit of ₹0.79 Cr. The EBITDA for H2 FY26 was ₹3.55 Cr, resulting in a margin of 22.24%.
| Metric | H2 FY26 | FY26 |
|---|---|---|
| Total Income | ₹ 15.96 Cr | ₹ 33.04 Cr |
| EBITDA | ₹ 3.55 Cr | ₹ 10.45 Cr |
| EBITDA Margin | 22.24% | 31.63% |
| Net Profit | ₹ 0.79 Cr | ₹ 4.87 Cr |
| Net Profit Margin | 4.94% | 14.74% |
| EPS | ₹ 0.79 | ₹ 4.90 |
During FY26, the company invested ₹12.96 Cr towards the purchase of fixed assets to support its long-term growth strategy. Depreciation expense increased by approximately 31% to ₹3.25 Cr in FY26 from ₹2.49 Cr in FY25.
Strategic Expansion
The company undertook several strategic initiatives during the period, including a joint venture entry into the Pune market. Invicta Diagnostic holds a 52% stake in the venture, which plans to establish diagnostic centres offering MRI, CT scan, and other services. The first centre has been secured at Market Yard, Pune.
Commercial operations commenced at the Dadar Centre on January 30, 2026, expanding the company's portfolio with PET-CT and CT scan facilities. The centre, located near Tata Memorial Hospital, was established with a project investment of approximately ₹5.50 Cr.
Additionally, the company received approval to acquire up to a 95% stake in Vinchurkar Diagnostics Private Limited, marking its entry into the Nashik market. The first phase of the acquisition was completed on May 8, 2026, securing a 51% controlling stake for a total consideration of ₹7.60 Cr.
Management Commentary
Sanket Vinod Jain, Chairman and Non-Executive Director, stated that FY26 was a landmark year with the company's NSE Emerge listing in December 2025. He highlighted the stable financial and operational performance, noting the maintenance of EBITDA margins in excess of 30%. The company remains focused on expanding its diagnostics network and driving sustainable growth in FY27.
Historical Stock Returns for Invicta Diagnostic
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.98% | -25.31% | -17.32% | -30.87% | -30.87% | -30.87% |
How quickly could the Pune joint venture diagnostic centres reach operational breakeven, and what revenue contribution is expected from the Market Yard centre in FY27?
Will the acquisition of the remaining 44% stake in Vinchurkar Diagnostics be completed in FY27, and how might full consolidation of Nashik operations impact overall margins?
Given the significant ₹12.96 Cr capex in FY26 and rising depreciation, how will the company balance further expansion investments while sustaining its 30%+ EBITDA margins in FY27?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
